TNF and panuveitis: A review of the medical history of these patients revealed that these subjects had been started on anti-TNF-α therapies due to a history of highly active disease, including recurrent panuveitis, pulmonary artery involvement, and central nervous system involvement, which did not respond to other immunosuppressive treatment.